Trellis Vitality Review: A Real 1/3/6-Month Price Table

Most GLP-1 programs make you reverse-engineer their pricing. Trellis Vitality (trellisvitality.com) prints a table — one month, three months, six months, both molecules, all doses — and labels the one-month column as the month-to-month rate rather than dividing a commitment down and calling it monthly.¹ That is rare enough on this bench to lead with.

It is also, as far as we can tell, the only part of its catalogue priced that way.

The GLP-1 table

Semaglutide is $150 a month at one month, $140 at three and $133 at six. Tirzepatide is $199, $189 and $179 on the same terms. All dosages are stated to cost the same, so your price does not climb as you titrate.

Multiplied out over twelve months: semaglutide is $1,800 month-to-month or $1,596 at the six-month rate — a $204 spread, or about 11%. Tirzepatide is $2,388 or $2,148, a $240 spread. That is a narrower commitment discount than most programs offer, which cuts both ways: less reward for locking in, and less penalty for staying flexible.

The header on the table says per-month price, with longer plans costing less per month. That sentence is doing real work. A provider that prints "$133/mo" without it is describing an $798 charge, and a reader who does not catch the difference budgets for a month and pays for half a year. We take every filed price from the one-month column for exactly this reason — the general failure mode is trap one in the true monthly cost of a GLP-1.

Where the transparency stops

Trellis runs four programs outside weight loss: NAD+, which it treats as its flagship, plus glutathione, a lipo-MIC and B12 injection, and tesamorelin. Each of them publishes exactly one number, prefixed "treatment plans starting at": $129, $93, $130 and $299 a month respectively.

There is no rung table behind any of those. We looked at the product pages, the build output and the intake flow, and no price ladder exists on the site for the non-GLP-1 line. So those four are "from" figures and nothing more, and we will not print them as monthly rates. Given the GLP-1 table's shape — where the six-month rung sits about 11% under the one-month rung — it is a reasonable guess that these are the longest-commitment prices and that the true month-to-month rate is higher. A reasonable guess is not an observation, and we file it as unverified rather than as a price.

Worth flagging: Trellis's own blog states twice that it publishes complete pricing on its program pages. For GLP-1 that is true. For the other four programs it is not, and the gap between the claim and the pages is the sort of thing our provider checklist exists to catch.

Who is behind the prescription

The dispensing pharmacy is named — VialsRX, a state-licensed compounding pharmacy in Houston — which puts Trellis in the minority of the programs we tested this month. The medical group is Arora Health & Aesthetics, LLC, with Dr. Sean Arora as medical director under NPI 1841729449, a number that resolves to an active family-medicine record in the national provider registry.²

That is the same medical group and the same medical director as The Edit. The two use different pharmacies and charge materially different prices, so they are separate products and you can reasonably prefer one on cost. What you cannot do is treat them as two independent clinical opinions or as a hedge against each other, and a shortlist containing both is narrower than it looks.

Coverage is stated as all 50 states. The legal operating entity is not named anywhere in the terms, which run to about three kilobytes of text — thin enough that the "no membership, no consult costs" claim is a marketing statement rather than a contractual one.

The claims we are not repeating

Trellis's pages carry a star rating, a current-patient count and an average annual savings figure, none of which is sourced anywhere on the site. We are not reprinting those numbers, because a number with no source behind it becomes a citation the moment somebody quotes it. Our own scoring approach is in the methodology, and it does not run on a provider's self-reported testimonial average.

The regulatory screen was clean: the trading name, the medical group and the pharmacy each returned zero company-column matches in the FDA's live warning-letter index in August 2026, in a pass whose positive control correctly returned a known 2026 letter for an unrelated seller.³

Where it lands on value

At $150 month-to-month for semaglutide, Trellis is the cheapest program on this bench that also publishes a real ladder, names its pharmacy and exposes a checkable NPI. Pepti beats it on sticker at $99 but names no pharmacy and publishes no NPI. The Edit matches its disclosure but charges $59 a month more for the same molecule.

If your shortlist is GLP-1 only, that combination is strong. If you were planning to add NAD+ or tesamorelin to the same account, you are buying a price you have not actually seen. Line it up on the cheapest semaglutide board, run twelve months through the cost calculator, and read the sourced background in our research library.